Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03077685 · ClinicalTrials.gov registry record · Phase 2
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
A Phase 2 study, sponsored by NanOlogy.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT03077685: Completed Phase 2 study, sponsored by NanOlogy.
NCT03077685 is a Phase 2 study that has completed, run by NanOlogy. The registered enrollment target is 54 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03077685, a Phase 2 study, has completed, sponsored by NanOlogy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
Open-label, dose-escalating, Phase IIa trial of NanoPac® to treat subjects with locally advanced pancreatic adenocarcinoma via direct intratumoral injection.
Primary Outcome
Treatment Emergent Adverse Events will include laboratory assessments, physical examination findings, and vital signs.
Interventions
- DRUG NanoPac®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2023-03-15 |
| Phase | Phase 2 |
What the finished NCT03077685 record still lists
NCT03077685 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 1 intervention - of which NanoPac® is the first listed.
NCT03077685 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03077685 about?
NCT03077685 is a clinical study titled "Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma". Open-label, dose-escalating, Phase IIa trial of NanoPac® to treat subjects with locally advanced pancreatic adenocarcinoma via direct intratumoral injection.
What is the current status of trial NCT03077685?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2017-12-01. Estimated completion is 2023-03-15.
What interventions are being tested in trial NCT03077685?
The interventions under investigation include: NanoPac® (DRUG).
Who is sponsoring clinical trial NCT03077685?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03077685's enrollment target sits among peer trials
54 1160th of 2000 higher than 830 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI